OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San ...
"The first platinum-based drug, cisplatin, has a powerful effect on cancer by binding to nuclear DNA, but it also affects normal cells and can cause serious side effects. We had data showing that some ...